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1146-114 Coronary Artery Disease in Patients With Multiple 
Emergency Department Visits and Negative Immediate 
Exercise Tests for Chest Pain: An Important Minority in 
a Total Cohort of Over 3,000 Low-Risk Patients 
Presenting With Chest Pain
Ezra A. Amsterdam, J. Douglas Kirk, Deborah Diercks, Larry Baker, Erin Madriago, 
Danny Yen, University of California, Davis, Sacramento, CA
Background: Low risk patients (pts) presenting to our emergency department (ED) with
chest pain undergo immediate exercise testing (IET).
Methods: IET was performed in all low risk pts presenting to the ED with chest pain and
results and clinical outcome were analyzed with particular reference to the group with
multiple visits and negative IETs.
Results: Of 3,432 patients tested during a 7.5 year interval, IET was positive in 353
(10.3%), nondiagnostic in 830 (24.2%) and negative in 2,249 (65.5%). During the study
period, 289 (13%) of the 2249 pts with negative tests had multiple (>2) IET for chest pain.
The total number of negative IET during the study period was 2,656 which were obtained
in 1,960 pts with single IET and in the multivisit (MV) subgroup of 289 pts who had 696
negative IET. Thus, the MV subgroup comprised 13% (289/2,249) of all pts with negative
IET but accounted for 26% (696/2656) of the total number of negative IET. In the MV sub-
group (n=289), 261 (90.3%) pts had 2-3 IET and 28 (8.7%) had >4 IET. The mean num-
ber of IET in the MV subgroup = 2.7 (range 2-7). The MV negative subgroup was similar
(p>0.05) in age (52 vs. 51 yr) and number of cardiac risk factors (1.5 vs. 1.5) to the single
negative IET pts but the proportion of women was higher in MV (54% vs. 44%, p<0.05).
In the MV negative IET pts, there was no cardiac mortality, 7 (2.4%) pts ultimately had
myocardial infarction and after a mean of 3.7 tests, 25 underwent cardiac catheterization
showing critical coronary artery disease and 24 (8.3%) of these pts had myocardial
revascularization.
Conclusions: Although a minority of negative IET pts had multiple visits to the ED, they
accounted for a disproportionate number of the IET by the entire negative group. An
important minority of the MV negative subgroup was ultimately found to have coronary
artery disease after multiple tests and were candidates for revascularization. Earlier
definitive evaluation of MV pts could obviate repeat visits in many and afford appropriate
therapy for coronary artery disease in an important minority.
ORAL CONTRIBUTIONS
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849-1 Uncoupling Proteins Shift During Cardiac Hypertrophy 
and Renin-Angiotensin System Suppression
Susan Marie Dallabrida, Maria Ann Rupnick, Brigham and Women's Hospital, Boston, 
MA, Children's Hospital, Boston, MA
Background: Improving energetics during heart failure may aid to preserve cardiac func-
tion. Uncoupling proteins (UCP) are key regulators of energetics in skeletal muscle and
adipose tissue. They reduce the proton electrochemical gradient across the innermito-
chondrial membrane. However, their role in cardiac tissue is poorly understood. In mice
with heart failure, increased UCP2 coincides with reduced high-energy phosphates. In
humans, reduced UCP3 in failing hearts is normalized with left ventricular assist devices.
RAAS suppression with angiotensin converting enzyme (ACE) inhibitors or angiotensin
receptor I (ATR1) blockers improve cardiac function and reduce remodeling. We asked if
these benefits were associated with improved cardiac energetics.
Methods: We examined UCP1, UCP2, UCP3 mRNA levels (real-time RT-PCR) in thy-
roid-hormone (T3)-induced cardiac hypertrophy (C57BL/6 mice) and in mice given T3
plus an antiangiogenic drug, TNP-470 on 1-4, 14 d. We measured the effect of captopril
or candesartan (14 d) on UCPs in C57BL/6 mice. Body, left/right ventricles, and atria
weights and tibia length were assessed.
Results: T3-induced hypertrophy increased left ventricle (LV) UCP2 and UCP3 mRNA
levels, and reduced UCP1. Compared to controls, UCP2 increased 5 fold (1, 2 d), 10 fold
(3 d), and 20 fold (4 d) with no further increases despite continued LV increases (14 d).
The UCP2 increases coincided with the most angiogenic phase (1-4 d) of T3-induced
hypertrophy. We examined the effects of an antiangiogenic agent, TNP-470, on UCP
shifts and hypertrophy. We treated mice with T3 plus TNP-470 (1, 4 d). TNP-470 reduced
UCP2 to normal and limited increases in LV mass (T3: 117+12 mg; T3+TNP-470: 94+6.0
mg), but did not negate UCP3 or UCP1 shifts. In addition, mice given captopril or cande-
sartan (14 d) had reduced UCP2 levels (2 fold) and LV weights (controls: 125+10; capto-
pril: 94+4; candesartan: 95+2 mg). UCP3 and UCP1 were unchanged.
Conclusion: UCPs may be important regulators of cardiac energetics. Perturbations
may contribute to heart failure. Agents that normalize UCP expressions (ie: TNP-470,
ACE inhibitors/ATR1 blockers) may improve cardiac function during hypertrophy and fail-
ure.
2:15 p.m.
849-2 Left Ventricular Assist Device Support Fails to 
Normalize the Beta-1/Beta-2 Adrenergic Receptor Ratio 
in Human Heart Failure
Wendy E. Sweet, Maria Yared, Monique L. Ogletree, Patrick M. McCarthy, James B. 
Young, Christine S. Moravec, Cleveland Clinic Foundation, Cleveland, OH
Background: Human heart failure is associated with a decreased response to beta-adr-
energic stimulation due to a decrease in beta-adrenergic receptors, particularly a
decrease in density of beta-1 receptors.During heart failure, the ratio of beta-1/beta-2
receptors is approximately 60/40, as compared to 80/20 in non-failing hearts. We have
shown that following left ventricular assist device (LVAD) support of the failing heart, total
receptor density recovers quickly, but recovery of the inotropic response to stimulation is
delayed. This study tested the hypothesis that delayed recovery of inotropy is due to a
delayed restoration in the ratio of beta-1/beta-2 adrenergic receptors.
Methods: Inotropic responsiveness to one micromolar isoproterenol was measured in
isolated, isometrically contracting human trabecular muscles from tissue removed at
LVAD implant and explant. Total beta receptor density were quantified in the same tissue
pairs by Scatchard analysis using radiolabeled cyanopindolol, while receptor subtypes
were determined by two-site competition binding curves using 15 doses of ICI 118,551.
Results: At time of LVAD explant, the inotropic response to isoproterenol was greater
(149 ± 29%) as compared to the time of implant (68 ± 14%, p < 0.05), and the response
continued to improve with increased duration of support (p < 0.05). Total receptor density
was increased after LVAD (72.3 ± 7.8 vs 24.2 ± 3.6 fmol/mg protein; p < 0.0001),
whereas the percent of beta-1 receptors was not different between the two groups (64.4
± 6.1% at implant; 68.4 ± 2.0% at explant). While the percent of beta-1 receptors was not
changed, the absolute number of both beta-1 (50.3 ± 6.4 vs 19.4 ± 3.5 fmol/mg protein, p
< 0.001) and beta-2 receptors (21.9 ± 2.2 vs 10.8 ± 2.6 fmol/mg protein, p < 0.05) was
increased after LVAD.
Conclusion: Although the total density of beta-adrenergic receptors recovers following
LVAD support of the failing human heart, the ratio of beta-1/beta-2 receptors remains at
failing (60/40) rather than non-failing (80/20) levels. The larger percentage of beta-2
receptors after LVAD may contribute to delayed recovery of the inotropic response.
2:30 p.m.
849-3 Extracellular Matrix Remodeling During Left Ventricular 
Assist Device Support: Relation Between Collagen and 
Passive Pressure-Volume Relations
Stefan Klotz, Marc L. Dickstein, Jeffrey A. Morgan, Robert F. Foronjy, Angou Gu, Jeanine 
D`Armentio, Daniel Burkhoff, Columbia University, New York, NY
Introduction: Left ventricular assist device (LVAD) support of failing hearts induces
reverse remodeling, manifest as shifts towards lower volumes of the passive pressure-
volume relationship (PVR). This may be a consequence of regression of hypertrophy
and/or changes in myocardial properties due to extracellular matrix remodeling. However,
the relative contributions of these factors to reverse remodeling are unknown.
Methods: LV tissue samples were collected from idiopathic dilated cardiomyopathic
(DCM) hearts at the time of cardiac transplantation in patients requiring (n=16) or not
requiring (n=16) prior LVAD support and from 5 normal hearts not suitable for transplan-
tation. Total collagen (hydroxyproline), soluble collagen and insoluble collagen were
determined. Chamber capacitance and myocardial stiffness were calculated from ex-vivo
PVRs and measured LV wall volume.
Results: Compared to normals, total collagen and soluble collagen were increased in
DCM (3.1±1.5 vs 6.1±3.4 µg/mg, p=0.014; 1.4±0.3 vs 4.1±0.9 µg/mg, respectively,
p<0.001). LVAD support further increased total collagen (9.0±3.3 µg/mg, p=0.019 vs
DCM), which was due to an increase of insoluble collagen (2.0±3.0 vs 5.1±3.1 µg/mg,
p=0.008) with no change in soluble collagen (4.1±0.9 vs 3.9±1.0, p=NS). LV mass was
decreased by LVAD support (296±73 vs 234±60 g, p=0.014), the PVR shifted towards
lower volumes with a chamber capacitance (volume at a pressure of 30 mmHg) decreas-
ing from 266±126 ml to 192±87 ml (p=0.024). However, myocardial stiffness constant
was not affected (9.9±0.7 vs 10.6±0.9, p=NS).
Discussion: LVAD-support of the failing human heart leads to increased total collagen
and cross-linking of collagen, suggestive of increased tensile strength of the extracellular
matrix. Despite these changes, however, global myocardial stiffness constant was unaf-
fected. These data lead to the provocative hypothesis that the profound changes induced
by LVADs indicative of reverse structural remodeling are mainly due to regression of myo-
cyte hypertrophy, with relatively little impact of the changes in collagen matrix on passive
myocardial properties.
2:45 p.m.
849-4 Soluble Tumor Necrosis Factor Receptor (Etanercept) 
Treatment Enhances Left Ventricular Dysfunction in an 
Experimental Model of Chronic Chagas Disease 
Cardiomyopathy
Angelina M. Bilate, Vera C. Salemi, Felix J. Ramires, Daniel Gregio, Jorge Kalil, Edecio 
Cunha-Neto, Heart Institute- University of São Paulo Medical School, São Paulo, Brazil
Background: chronic Chagas’ disease cardiomyopathy (CCC), caused by the protozoan
Trypanosoma cruzi, affects ca. 3 million patients in Latin America. The lack of proven effi-
cacious therapy is associated with worse prognosis of CCC. Chagas’disease is associ-
ated to increased production of proinflammatory cytokines such as TNF-alpha. The aim
of this work was to evaluate Etanercept, a TNF-blocking agent, as a potential therapeutic
approach in the control of CCC development. For that matter, we used as a model the
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chronically T. cruzi infected Syrian hamster, shown by our group to develop a cardiomy-
opathy resembling human CCC.
Methods: female Syrian hamsters were injected intraperitoneally with 105 Y strain T. cruzi
parasites (40) or saline solution (20, N group). At 9 months post-infection (PI), surviving
infected animals were divided in 2 groups: (T) treated with 2.5mg of Etanercept/Kg body
weight s.c. 2x/week for 9 weeks and (I) no further treatment. Animals were subjected to
2-D, pulsed-wave color Doppler and M mode echocardiography, under tribromoethanol
anesthesia, at three time points: before T. cruzi infection, at 8 ½ and 11 months PI. At 11
months PI, animals were euthanized, and heart/body weight index (HW/BW) was calcu-
lated.
Results: median baseline echocardiographic measurements were similar between all
treatment groups. Deaths between 9 and 11 months PI were more frequent in the T (8/
13) than in I group (4/10). At 11 months PI, fractional shortening (FS) was significantly
diminished in the T (22.0 [9.5-47.7]) as compared to the I group (36.6 [25.7-43.9]
(median [min-max]). Left ventricle diastolic diameter (LVDD) and HW/BW index were sig-
nificantly increased at 11 months PI in the T group (0.63 [0.41-0.73]; 6.1 [4.0-8.7],
respectively) as compared to I group (0.57 [0.46-0.67]; 4.1 [4.3-5.9], respectively). In the
T group, FS and LVDD were significantly different between 8 ½ and 11 months PI, but
remained similar in I or N groups.
Conclusions: TNF blockade worsens left ventricular dysfunction in chronically T. cruzi
infected hamsters. Therefore, Etanercept should not be considered for the treatment of
CCC patients.
3:00 p.m.
849-5 Alterations in Cell Signaling Pathways During 
Pregnancy and Postpartum Cardiac Remodeling
Ana M. Duque Gonzalez, Juan C. Osorio, Seema Mital, Columbia University, New York, 
NY
Background: The cardiac molecular changes induced by load during pregnancy are not
well understood. We investigated the role of mitogen-activated protein kinases (MAPK),
protein kinase B (Akt) and endothelial nitric oxide synthase (eNOS) in post-partum (PP)
cardiac remodeling.
Methods: Adult female Sprague-Dawley rats were divided into non-pregnant (n=5), 16
days (d) pregnant (n=4), PP d0 (n=7), PP d8 (n=6), and PP d14 (n=10). Rats underwent
serial 2-D echocardiography to measure cardiac size and function. Protein expression in
ventricular myocardium was measured by Western blot for MAPKs (p38, p44/42, JNK),
protein kinase B (Akt) and eNOS. Blot density was expressed in arbitrary units (AU).
Results: Echocardiography: During pregnancy, there was an increase in LV ejection frac-
tion (EF) (63.7±3% to 73.7±1.6%, p<0.05) and LV mass (0.62±0.03 to 1.1±0.04 g,
p<0.01), and decrease in LV systolic area (LVSA) (0.3±0.01 to 0.23±0.02 cm2, p<0.05).
In the immediate PP period, LV function decreased by 23% (EF= 56.5±2.9%, p<0.01), LV
diastolic area increased by 13%, and LVSA by 56%. By PP d14, LV mass decreased,
however, LV dilatation and dysfunction persisted. Protein expression: MAPK expression
did not change during pregnancy. However, p44/42 increased (29±1 to 37±1 AU) and p38
MAPK decreased (35±2 to 22±2 AU) by PP d14 (p<0.01). Akt and eNOS peaked at PP
d14 (p<0.01). LV mass showed a positive correlation with p38 MAPK (r=0.7) and an
inverse correlation with p44/42 (r=0.72). LVDA inversely correlated with JNK expression
(r=0.76).
Conclusion: The PP period is characterized by LV wall thinning, dilatation and dysfunc-
tion possibly related to an increase in myocardial p44/42 and decrease in p38 MAPK
expression, mediators of cardiac hypertrophic responses. The concomitant increase in
Akt and eNOS also suggests a role for Akt-dependent pathways. Understanding the sig-
naling pathways of physiologic cardiac remodeling can be used to better characterize
pathological processes like PP cardiomyopathy.
3:15 p.m.
849-6 Apoptotic Cleavage of Contractile Proteins in End-Stage 
Heart Failure
Lorenz Bott-Fluegel, Hans-Joerg Weig, Karl-Ludwig Laugwitz, Michael Naebauer, Diana 
Grewe, Melchior Seyfarth, Medizinische Klinik and Deutsches Herzzentrum, Technische 
Universitaet, Munich, Germany, Medzinische Klinik und Poliklinik, Klinikum Grosshadern, 
LMU Muenchen, Munich, Germany
Background: There is strong evidence that apoptosis plays an important part in the
pathogenesis of heart failure. In a previous study we showed that activated caspase-3
cleaves the essential myosin light chain-1 (MLC-1) in tachycardia-induced heart failure in
rabbits. However, it is unclear to what extent this apoptotic program is executed in human
heart failure. Therefore, we examined human myocardial samples for the cleavage of
contractile proteins. Methods: Myocardial specimens from 6 patients with either ischemic
cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) wererapidly collected after
explantation and stored at -80 °C. The samples were then minced and lysed, and cytoso-
lic and nuclear fractions were prepared. After electrophoresis and blotting, samples were
probed with the respective antibody. Low-abundancy proteins including MLC-1 and
caspase-3 were enriched by immunoprecipitation with the specific antibody, and then
electrophoresed as above.
Results: Caspsase-3 activation was demonstrated in 60% of DCM and 55% of ICM
hearts. Cleavage of common targets of caspase-3, such as poly-(ADP-ribose)-poly-
merase (PARP), a DNA repair enzyme, or gelsolin was shown in 75% of DCM and 80%
of ICM hearts. Furthermore, we showed that MLC-1 was cleaved in myocardial speci-
mens of DCM (90%) and ICM (75%) patients. Other structural or contractile proteins like
myosin heavy chain (MHC), alpha sarcomeric actin, troponins, tropomyosin, and alphaB
crystallin were not cleaved. Fragmentation of DNA could be observed only in a fraction of
hearts, 15% in the DCM and 20% in the ICM group.
Conclusion: In this study we demonstrated that caspase-3, a key apoptosis protein, is
activated in human heart failure. We observed cleavage of PARP, a nuclear DNA repair
protein and typical target of caspases. Cleavage of the contractile protein MLC-1 was
found in 75-90% of human heart failure specimens, suggesting that apoptotic cleavage of
contractile proteins also occurs in human heart failure and may partially explain the dete-
rioration of ventricular function. Other contractile proteins were not cleaved.
POSTER SESSION
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1163-109 Ongoing Myocardial Damage in Severe Heart Failure: 
Prognostic Usefulness of Cardiac Troponin T 
Monitoring to Identifying High-Risk Patients
Eduardo R. Perna, Stella M. Macin, Juan P. Cimbaro Canella, Natalia Augier, Ariel E. 
Pitzus, Jorge L. Riera Stival, Jorge Cialzeta, Edgar Garcia, Alejandro Barbagelata, Eloisa 
Jantus, Instituto de Cardiologia J. F. Cabral, Corrientes, Argentina, Hospital Italiano, 
Buenos Aires, Argentina
Background: The progression of heart failure (HF) is related to myocyte loss due to sev-
eral abnormalities, and it can be detected by cardiac troponin T (cTnT). We assessed the
hypothesis that cell loss overtime in stable HF could identifiy a subgroup with worse prog-
nosis.
Methods: Clinical, echocardiographic and 6 minute walk test data were prospectively
obtained baseline and after one year in 115 outpatients with HF and LVEF less than 40%.
Baseline, 3, 6 and 12 months blood samples were assayed for cTnT (3rd generation) and
levels >=0.02 ng/mL were considered abnormal. Patients were classified as Group 1: all
cTnT samples (-), Group 2: one cTnT (+), and Group 3 two or more cTnT (+).
Results: Mean age was 61±11 years, 75% were male and 62% had coronary heart dis-
ease. Population was classified in Group 1=62(54%), 2=28(24%), and 3=25(22%). Com-
parison is detailed in Table. Eighteen-month free HF-hospitalization survival in Groups 1,
2 and 3 was 63, 46 and 17% (p=0.0001), and in a Cox-proportional hazard model, the
variables independently associated with events were the following: compensated HF at
admission (HR=0.42,95%CI=0.20-0.89,p=0.029), NYHA class III-IV
(HR=2.0,95%CI=1.13-3.7,p=0.019) and number of positive samples for cTnT
(HR=1.9,95%CI=1.4-2.6,p<0.0001).
Conclusion: cTnT elevation in severe HF correlated with disease severity and functional
deterioration. Moreover, myocardial damage was a strong predictor of worsening HF,
suggesting a role of cTnT-based monitoring to detect high risk patients
1163-110 Clinical and Prognostic Role of IgG3 Autoantibodies in 
Patients With Heart Failure: A Substudy of the 
Vasogen's Immunmodalatory Therapy
Rahat S. Warraich, James B. Young, Francois Sestier, Katy Becker, Susan McRee, 
Magdi H. Yacoub, Guillermo Torre-Amione, Harefield Hospital, NHLI of Imperial College, 
Middlesex, United Kingdom
Clinical benefits of Vasogen's Immune Modulation Therapy (IMT) have been reported in a
No. of inflammatory conditions. Results from a recent multi-center, double-blind, placebo-
controlled study using this novel non-pharmacological, anti-inflammatory treatment regi-
men in patients (pts) with chronic heart failure (HF) demonstrated a reduction in the risk
of all-cause mortality and hospitalization (hosp) in the treatment vs placebo group. How-
ever, the potential targets for this treatment in HF are not known. We have previously
identified an immunoglobulin (Ig) subclass G3 response in pts with HF. Given the poten-
tial capacity of G3-Igs to mediate tissue injury, the study sought to investigate the clinical
relevance of class/subclass-Igs and cytokines in the IMT-study cohort.
Levels of Igs, total (Gt) and subclasses; G1, G2 and G3 against human cardiac myosin,
TNF-α , INF-γ , IL-6 and IL-10 were evaluated (blindly) in 71 study pts (mean LVEF 22%,
NYHA class III/IV). Pts in both groups (IMT; n=36, placebo; n=35) were matched for age,
gender, functional class (fc), exercise tolerance and drug therapy. Baseline levels of Ig-
Gt, 1, 2, and the cytokines were similar in both groups, whereas G3-response was non-
significantly lower in the IMT group vs placebo; 0.19 (0.09-0.40) and 0.37 (0.1-0.54),
Table (* p<0.02 vs baseline)
Group 1 Group 2 Group 3 p value
NYHA Class, mean (SD) Baseline 2.3(0.8) 2.5(0.7) 2.5(0.8) 0.25
12 months 2.4(0.8) 2.7(0.7) 3.3(0.6)* <0.0001
EF, % (SD) Baseline 28.5(8) 22.3(8) 25.4(8) 0.003
12 months 36(11)* 32.7(12)* 30.1(11) 0.17
Mortality, % 12 months 8.1 28.6 12 0.032
Emergency visit for worsening 
HF, % 
12 months 22.6 60.7 88 <0.0001
